ArticleAmerican journal of respiratory cell and molecular biology2010
Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi.
Article in American journal of respiratory cell and molecular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02148796 (Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness), which is not on this map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)
Who cites it
77 citing papers in PubMed, 127 citations in OpenAlex.
- Phosphorothioate backbone modification of oligodeoxynucleotides induces TLR9-independent lung epithelial antimicrobial responses.American journal of respiratory cell and molecular biology · 2026Article
- OM85 ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting Notch expression and modulating the IFN-γ/IL-4 ratio.Scientific reports · 2025Article
- The RNA receptor RIG-I binding synthetic oligodeoxynucleotide promotes pneumonia survival.JCI insight · 2024Article
- Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer.Journal of immunology research · 2024Review
- Antimicrobial mitochondrial reactive oxygen species induction by lung epithelial immunometabolic modulation.PLoS pathogens · 2023Article
- Epithelial STAT3: A New Twist in Inducible Antimicrobial Resistance.American journal of respiratory cell and molecular biology · 2023Article
- Redox-Dependent Activation of Lung Epithelial STAT3 Is Required for Inducible Protection against Bacterial Pneumonia.American journal of respiratory cell and molecular biology · 2023Article
- The Serum Level of CXCL9, CXCL10, and CXCL11 and the Expression of CXCR3 of Peripheral Blood Mononuclear Cells in Brucellosis Patients.Current microbiology · 2023Article
- Antimicrobial mitochondrial reactive oxygen species induction by lung epithelial metabolic reprogramming.bioRxiv : the preprint server for biology · 2023Article
- Pre-exposure to Aerosolized Polyvalent Bacterial Lysates Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice.Inflammation · 2022Article
- The effect of aerosolized bacterial lysate on experimentally inducedCanadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2022Article
- Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease.Frontiers in immunology · 2022Review
- Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in mice.Frontiers in pharmacology · 2022Article
- Promising Immunomodulatory Effects of Bacterial Lysates in Allergic Diseases.Frontiers in immunology · 2022Review
- Bovine innate immune phenotyping via a standardized whole blood stimulation assay.Scientific reports · 2021Article
- Effect of aerosolized bacterial lysate on development of naturally occurring respiratory disease in beef calves.Journal of veterinary internal medicine · 2021Article
- Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation.Frontiers in immunology · 2021Article
- CD8American journal of respiratory cell and molecular biology · 2020Article
- Inducible Epithelial Resistance against Coronavirus Pneumonia in Mice.American journal of respiratory cell and molecular biology · 2020Article
- Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.medRxiv : the preprint server for health sciences · 2020Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
Pneumonia is a serious problem worldwide. We recently demonstrated that innate defense mechanisms of the lung are highly inducible against pneumococcal pneumonia. To determine the breadth of protection conferred by stimulation of lung mucosal innate immunity, and to identify cells and signaling pathways activated by this treatment, mice were treated with an aerosolized bacterial lysate, then challenged with lethal doses of bacterial and fungal pathogens. Mice were highly protected against a broad array of Gram-positive, Gram-negative, and class A bioterror bacterial pathogens, and the fungal pathogen, Aspergillus fumigatus. Protection was associated with rapid pathogen killing within the lungs, and this effect was recapitulated in vitro using a respiratory epithelial cell line. Gene expression analysis of lung tissue showed marked activation of NF-kappaB, type I and II IFN, and antifungal Card9-Bcl10-Malt1 pathways. Cytokines were the most strongly induced genes, but the inflammatory cytokines TNF and IL-6 were not required for protection. Lung-expressed antimicrobial peptides were also highly up-regulated. Taken together, stimulated innate resistance appears to occur through the activation of multiple host defense signaling pathways in lung epithelial cells, inducing rapid pathogen killing, and conferring broad protection against virulent bacterial and fungal pathogens. Augmentation of innate antimicrobial defenses of the lungs might have therapeutic value for protection of patients with neutropenia or impaired adaptive immunity against opportunistic pneumonia, and for defense of immunocompetent subjects against a bioterror threat or epidemic respiratory infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.